These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1517889)

  • 1. P53 in tumour pathology: can we trust immunocytochemistry?
    Wynford-Thomas D
    J Pathol; 1992 Apr; 166(4):329-30. PubMed ID: 1517889
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutational analysis of p53 in human tumors: immunocytochemistry.
    Slade N; Moll UM
    Methods Mol Biol; 2003; 234():231-43. PubMed ID: 12824536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
    Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
    Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.
    Farid P; Gomb SZ; Péter I; Szende B
    Neoplasma; 2001; 48(4):299-301. PubMed ID: 11712682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
    van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
    J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp70 interactions with the p53 tumour suppressor protein.
    Zylicz M; King FW; Wawrzynow A
    EMBO J; 2001 Sep; 20(17):4634-8. PubMed ID: 11532927
    [No Abstract]   [Full Text] [Related]  

  • 7. The significance of p53 mutations in human cancers.
    Pellegata NS; Ranzani GN
    Eur J Histochem; 1996; 40(4):273-82. PubMed ID: 9116334
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation between p53 gene mutations and p53 protein accumulation evaluated by different methodologies.
    Calistri D; Barzanti F; Dal Susino M; Fedriga R; Saragoni L; Bernardi L; Ricotti L; Zoli W
    J Biol Regul Homeost Agents; 2000; 14(2):120-7. PubMed ID: 10841287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
    Omar E; Madhavan M; Othman NH
    Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The tumor suppressor gene p53 (part 2). Applications in human pathology].
    Martin A
    Ann Pathol; 1995; 15(3):184-91. PubMed ID: 7639854
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
    Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
    Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour suppressor genes and molecular chaperones.
    Lane DP; Midgley C; Hupp T
    Philos Trans R Soc Lond B Biol Sci; 1993 Mar; 339(1289):369-72; discussion 372-3. PubMed ID: 8493291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
    Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
    Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
    Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
    Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors.
    Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
    Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
    Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
    Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p53-homologue p63 may promote thyroid cancer progression.
    Malaguarnera R; Mandarino A; Mazzon E; Vella V; Gangemi P; Vancheri C; Vigneri P; Aloisi A; Vigneri R; Frasca F
    Endocr Relat Cancer; 2005 Dec; 12(4):953-71. PubMed ID: 16322335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 is an independent prognostic factor for survival in thyroid cancer.
    Bachmann K; Pawliska D; Kaifi J; Schurr P; Zörb J; Mann O; Kahl HJ; Izbicki JR; Strate T
    Anticancer Res; 2007; 27(6B):3993-7. PubMed ID: 18225561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
    Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
    Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.